melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glut1 reactivity was absent in the melanomas and seborrheic keratoses.
|
9344196 |
1997 |
melanoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Our results suggest that glucose transporter Glut-1 expression can significantly discriminate between human malignant melanoma and benign melanocytic nevi, and support the idea that additional mechanisms other than Glut-1 may contribute to glucose uptake in melanomas.
|
18764953 |
2008 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the effects on overall or disease free survival in melanoma patients were modest or absent for GLUT-1 or for HIF-1α, respectively.
|
24997364 |
2014 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, we have determined that the l-cysteine/CSE/H2 S pathway is involved in melanoma progression.
|
25205294 |
2015 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment of four different human melanoma cell lines with a pharmacological GLUT1 inhibitor caused a dose-dependent reduction of proliferation, apoptosis resistance, migratory activity and MMP2 expression.
|
26293674 |
2015 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, silencing of GLUT1 in the melanoma cells resulted in the increased expression of WNT5A and the decreased ability of invasion and proliferation in the melanoma cells.
|
26934938 |
2016 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, CD147 and GLUT-1 were co-localized in the cytoplasm of human melanoma A375 cells.
|
27556188 |
2016 |
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Tissue samples from normal skin, melanocytic naevi and melanoma were subjected to immunohistochemistry for two TT-Cs (Cav3.1, Cav3.2); markers of proliferation (Ki67), the cell cycle (cyclin D1), hypoxia (Glut1), vascularization (CD31) and autophagy (LC3); BRAF V600E mutation (VE1) and phosphatase and tensin homologue (PTEN).
|
27718503 |
2017 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The number of positive cases and the H-score of Glut-1 increased where there was a higher Breslow thickness (p < 0.00001) when comparing pT1- pT4 MM groups.
|
29128957 |
2019 |
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Increased GLUT1 (Glucose Transporter Type 1) expression has been demonstrated earlier in malignant melanomas.
|
29929176 |
2018 |
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Of melanoma cases, 85.3% expressed either GLUT1 or GLUT3 or both, 39.4% of melanoma cases coexpressed GLUT1 and GLUT3, 17.4% of melanoma cases only expressed GLUT1, 28.4% of melanoma cases only expressed GLUT3, and 14.7% of melanoma cases were negative for both markers.
|
31135601 |
2019 |
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusions:</b> We concluded that ITCH may downregulate GLUT1 and suppresses glucose uptake in melanoma to inhibit cancer cell proliferation.
|
31403357 |
2019 |
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
While under normoxic conditions the expression of glycolysis-related genes showed no correlation with origin or BRAF mutation status, GLUT1 expression was significantly elevated in metastatic and BRAF-V600E mutated melanoma cell lines under hypoxic conditions.
|
31791701 |
2020 |